Answers are grounded in this paper and cite their sources.
Castration-resistant prostate cancer (CRPC) represents a significant clinical challenge, characterized by resistance to androgen receptor antagonists such as enzalutamide (ENZ) and by immune tolerance mechanisms. Although monoamine oxidase A (MAOA) has been implicated in prostate cancer progression, its role in CRPC drug resistance and immune suppression remains underexplored. We investigated the role of MAOA in CRPC drug resistance and immune evasion using a series of in vitro and in vivo models, including ENZ-resistant cell lines, patient-derived organoid (PDO) models, patient-derived xenograft (PDX) models, and humanized mouse models. Our findings revealed that MAOA was significantly upregulated in ENZ-resistant CRPC models. Yes-associated protein 1 (YAP1) may link MAOA-associated drug resistance and immune evasion. In tumor cells, MAOA-associated YAP1 signaling is linked to alterations in reactive oxygen species (ROS) levels and NF-κB-related signaling, potentially contributing to ENZ resistance. Furthermore, MAOA-associated YAP1 signaling regulates tumor-cell PD-L1 expression and may contribute to immune evasion. In preclinical models, the combination of ENZ, MAOA inhibition, and PD-1 blockade exhibited enhanced antitumor efficacy compared with the other ENZ-containing treatment regimens. These findings suggest potential therapeutic benefits of targeting MAOA in CRPC. Combining MAOA inhibitors with ICIs could improve patient outcomes by addressing both intrinsic drug resistance and extrinsic immune evasion.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: